Subcutaneous beloranib: Completed Phase IIa enrollment

Zafgen completed enrollment of 14 obese patients with radiog*raphically confirmed hypothalamic damage in the double-blind, placebo-controlled, U.S. and Australian Phase IIa ZAF-221 trial evaluating 1.8 mg subcutaneous beloranib given twice weekly for 4 weeks. The trial includes a 4-week, open-label extension period. ...